Previous Close | 0.833 |
1-Year Change | -25.63% |
6-Months Change | -5.34% |
3-Months Change | 43.87% |
Moving Avg (50d) | 0.8468 |
Moving Avg (200d) | 0.8966 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 107.1M |
Beta (3-Years) | 1.29 |
Revenue Growth (ttm) | 851.37% |
Net Profit Margin (ttm) | -111.03% |
Return On Assets (ttm) | -38.42% |
EPS (ttm) | -1.12 |
PE Ratio (ttm) | -0.74 |
Dividend Yield | % |
Asset Description: | Seres Therapeutics, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2025-02-13 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.816 | 0.791 | 0.775 | 0.75 | 0.708 | 0.666 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |